A small molecule inhibitor of Rheb selectively targets mTORC1 signaling

Sarah J. Mahoney (), Sridhar Narayan, Lisa Molz, Lauren A. Berstler, Seong A. Kang, George P. Vlasuk and Eddine Saiah
Additional contact information
Sarah J. Mahoney: Navitor Pharmaceuticals, Inc.
Sridhar Narayan: Navitor Pharmaceuticals, Inc.
Lisa Molz: Navitor Pharmaceuticals, Inc.
Lauren A. Berstler: Navitor Pharmaceuticals, Inc.
Seong A. Kang: Navitor Pharmaceuticals, Inc.
George P. Vlasuk: Navitor Pharmaceuticals, Inc.
Eddine Saiah: Navitor Pharmaceuticals, Inc.

Nature Communications, 2018, vol. 9, issue 1, 1-12

Abstract: Abstract The small G-protein Rheb activates the mechanistic target of rapamycin complex 1 (mTORC1) in response to growth factor signals. mTORC1 is a master regulator of cellular growth and metabolism; aberrant mTORC1 signaling is associated with fibrotic, metabolic, and neurodegenerative diseases, cancers, and rare disorders. Point mutations in the Rheb switch II domain impair its ability to activate mTORC1. Here, we report the discovery of a small molecule (NR1) that binds Rheb in the switch II domain and selectively blocks mTORC1 signaling. NR1 potently inhibits mTORC1 driven phosphorylation of ribosomal protein S6 kinase beta-1 (S6K1) but does not inhibit phosphorylation of AKT or ERK. In contrast to rapamycin, NR1 does not cause inhibition of mTORC2 upon prolonged treatment. Furthermore, NR1 potently and selectively inhibits mTORC1 in mouse kidney and muscle in vivo. The data presented herein suggest that pharmacological inhibition of Rheb is an effective approach for selective inhibition of mTORC1 with therapeutic potential.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-03035-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03035-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-03035-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().